Results 171 to 180 of about 6,571 (189)

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

Diabetes, Obesity and Metabolism, 2009
Bo Ahrén, S Dejager, B Zinman
exaly  

Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study

Diabetes, Obesity and Metabolism, 2010
Bo Ahrén, S Dejager
exaly  

Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus

Diabetes, Obesity and Metabolism, 2013
Baptist Gallwitz, W Kothny, J Foley
exaly  

VILDAGLIPTIN

2010
openaire   +1 more source

A case of bullous pemphigoid ınduced by vildagliptin

Cutaneous and Ocular Toxicology, 2017
Özay Gököz, Sibel Ersoy-Evans, Müzeyyen Gönül   +2 more
exaly  

Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus

Diabetes Research and Clinical Practice, 2009
Mitsutoshi Kato, Masatoshi Kikuchi
exaly  

Physicochemical Properties and Methods of Analysis of Vildagliptin (Review)

Pharmaceutical Chemistry Journal, 2022
exaly  

Dual therapy of vildagliptin and telmisartan on diabetic nephropathy in experimentally induced type 2 diabetes mellitus rats

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2014
Prashant Kumar Dhakad, Ashish Kumar Sharma   +1 more
exaly  

The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin

European Journal of Clinical Pharmacology, 2007
R Sabo, Y L He
exaly  

Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV

British Journal of Clinical Pharmacology, 2012
Yan-Ling He, Cornelia Barbara Landersdorfer, William J Jusko   +2 more
exaly